## Abstract ## BACKGROUND. The American Joint Committee on Cancer (AJCC) staging system for prostate cancer is based primarily based on clinical tumor (T) classification. In this article, the authors summarize arguments for incorporating additional pretreatment parameters and creating a new stagin
Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer
β Scribed by Rinaa S. Punglia; Jennifer Cullen; David G. McLeod; Yongmei Chen; Anthony V. D'Amico
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 80 KB
- Volume
- 110
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
BACKGROUND.
An increasing prostateβspecific antigen (PSA) velocity is associated with a shorter survival after local therapy for prostate cancer. In this study, the authors evaluated whether PSA velocity was associated with prostate cancer detection and grade at diagnosis after adjusting for established predictors.
METHODS.
Between January 1989 and December 2003, 914 men who had PSA levels β₯4 ng/mL were identified by using the Center for Prostate Disease Research (CPDR) multicenter national database, including 541 men who were diagnosed with prostate cancer. Multivariable logistic regression analyses were performed that included continuous variables (PSA velocity and level, number of prior negative biopsies, and age) along with categorical variables (ethnicity and family history) were used to identify the factors associated with prostate cancer detection and grade.
RESULTS.
An increasing PSA velocity was associated with Gleason scores from 7 to 10 versus Gleason scores form 2 to 6 or no cancer (adjusted odds ratio [OR], 1.04 ng/mL per year; 95% confidence interval [95% CI], 1.003β1.085 ng/mL per year; P = .035). This finding was not evident in patients who had prostate cancers with Gleason scores between 2 and 6 or for any prostate cancer. PSA level was associated with the detection of any prostate cancer (OR, 1.06 ng/mL; 95% CI, 1.03β1.10 ng/mL; P = .004) and Gleason score β€6 prostate cancer (OR, 1.06 ng/mL; 95% CI, 1.02β1.10 ng/mL; P = .0027); however, in the presence of PSA velocity, PSA no longer remained independently predictive for highβgrade prostate cancer (OR, 1.01 ng/mL; 95% CI, 0.98β1.04 ng/mL; P = .45) after adjusting for established predictors.
CONCLUSIONS.
PSA velocity enhanced the detection of highβgrade cancer in men who had PSA levels >4 ng/mL. These findings, in conjunction with life expectancy, may be used when deciding which men should not be recommended for prostate biopsy despite a PSA level >4 ng/mL. Cancer 2007. Β© 2007 American Cancer Society.
π SIMILAR VOLUMES
## BACKGROUND. The stage specific survival rates of black American men with prostate carcinoma are less favorable than those of white American men. The authors conducted a prospective study of the serum prostate specific antigen (PSA) concentrations and Gleason histologic scores of black and white
## BACKGROUND. Early (Υ 2 years) prostate specific antigen (PSA) failure after radical prostatectomy (RP) has been shown to predict for distant failure. After excluding patients with the pathologic predictors of early PSA failure, an analysis of PSA failure free (bNED) survival was performed to ide
In a study population, can digital rectal examination (DRE), transrectal ultrasound (TRUS), and prostate specific antigen (PSA) (monoclonal) effectively detect the majority of clinically relevant cancer? If this is possible, the remaining patients could then be considered for chemopreventive protoco
## Abstract ## BACKGROUND The purpose of this study was to compare predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormoneβsensitive prostate cancer (HSPC) either with (M+) or without (Mβ) metastases. ## METHODS A cohort of prostate cancer patients was ident